|
National Conference Offers Insider View of Vioxx Litigation Issues
Legal and Experts to Share Latest Developments and Outlook at Mealey's Vioxx Litigation Conference Sponsored by LexisNexis
DAYTON, OH, June 15, 2005 - As the landscape surrounding Merck’s Vioxx legal battle continues to revolutionize, LexisNexis®, a leader in legal, news and business information services, will host the Mealey’s Vioxx Litigation Conference on June 22-23 at the Hotel Intercontinental New Orleans.
The conference will bring together all parties impacted by the pending Vioxx lawsuits, including plaintiff and defense attorneys, physicians, pharmacologists, legislators and financial analysts. Topics that will be addressed at the conference include:
- Up-to-the-minute look at ongoing discovery – hot documents and testimony
- Update on recently completed Vioxx trials
- Insider" results from a real Vioxx jury focus group
- The status of Multi District Litigation (MDL) and consolidated actions in New Jersey, California and Texas
- Status of the Congressional FDA Advisory Panel, FDA actions and other regulatory issues
- Medical, scientific and diagnostic issues critical to general and specific causation
- Potential litigation beyond Vioxx
For registration information on the Mealey’s Vioxx Litigation Conference, visit www.mealeys.com/conferences call 1-800-MEALEYS.
Editors Note: LexisNexis Vioxx litigation expert Michael Lefkowitz will be available to provide in-depth information regarding all conference topics, as well as insight on the implications of the following:
- Major drug product litigation in general as it relates to arthritis and diabetes drugs and vaccines
- Historical background for existing mass torts involving Fen-Phen/Redux, Thimerosal and Propulsid, and other major drug brands
- Mass drug tort reform in the United States
- Impact of litigation on drug import laws in the United States
To schedule a briefing with Michael Lefkowitz at the Mealey’s Vioxx Litigation Conference or via phone, please contact Erin Bocherer at (614) 825-1796.
About LexisNexis
LexisNexis® (www.lexisnexis.com) is a leader in comprehensive and authoritative legal, news and business information and tailored applications. A member of Reed Elsevier Group plc [NYSE: ENL; NYSE: RUK] (www.reedelsevier.com), the company does business in 100 countries with 13,000 employees worldwide. In addition to its flagship Web-based Lexis® and Nexis® research services, the company includes some of the world’s most respected legal publishers such as Martindale-Hubbell, Matthew Bender, Butterworths, Les Editions du Juris-Classeur, Abeledo-Perrot and Orac.
Editor's Note: Media are invited to attend the conference compliments of LexisNexis. For more information or to receive credentials, contact Erin Bocherer at (614) 825-1796 or erin.bocherer@fahlgren.com.
|
